Colorectal Cancer Treatment Market is expected to reach US$ 24.74 Billion by 2031

Surgery Segment Based on Treatment Fuels Colorectal Cancer Treatment Market Growth

According to our new research study on “Colorectal Cancer Treatment Market Forecast to 2031 – Global Analysis – by Treatment, Age Group, and End Users,” the colorectal cancer treatment market size is expected to grow from US$ 19.93 billion in 2024 to US$ 24.74 billion by 2031. The market is expected to register a CAGR of 3.2% during 2025–2031. Major factors driving the growth of the colorectal cancer treatment market include the growing number of colorectal cancer cases and increasing advancements in targeted and immunotherapies.

Colorectal cancer treatment involves a combination of therapies based on the cancer's stage and location. Early-stage disease is typically treated with surgery to remove tumors. In more advanced stages, treatment may include chemotherapy, radiation therapy, and targeted or immunotherapy for tumors with specific genetic markers. For metastatic cases, systemic therapies help control disease spread. Personalized treatment plans are developed using molecular profiling. Supportive care addresses symptoms, nutrition, and quality of life.

Colorectal Cancer Treatment Market, by Region, 2024(%)

Source: The Insight Partners Analysis

Colorectal Cancer Treatment Market Analysis Based on Segmental Evaluation:

Based on treatment, the colorectal cancer treatment market is categorized into surgery, chemotherapy, immunotherapy, targeted therapy, and others. In 2024, the surgery segment held a significant colorectal cancer treatment market share. Surgery remains the cornerstone treatment for localized and advanced colorectal cancer, with innovations such as robotic-assisted and laparoscopic surgeries improving outcomes and reducing recovery times. The rising burden of colorectal cancer (CRC)—projected to reach 3.2 million new cases annually by 2040, as per the World Health Organization (WHO)—further fuels demand for surgical interventions. The demand for surgical interventions has grown significantly due to early diagnosis facilitated by improved screening programs such as colonoscopies and fecal immunochemical tests (FIT), which detect precancerous polyps or cancer at an operable stage. According to the American Cancer Society, over 60% of CRC cases in high-income countries are now detected in early stages, where surgical resection offers a potential cure. This early detection directly translates into greater reliance on surgical procedures as a first-line treatment, thereby boosting the colorectal cancer treatment market segment’s growth.

The market is segmented by age group into below 49 years, 50–64 years, and above 65 years. The above 65 years segment held the largest share of the colorectal cancer treatment market in 2024 and is anticipated to register the highest CAGR during 2025–2031. As global populations age, the proportion of individuals aged 65 and above is rising significantly. According to the WHO, by 2030, 1 in 6 people worldwide will be 60 or older, with the 80+ age group growing the fastest. Since age is the single most significant risk factor for colorectal cancer—with ~75% of cases diagnosed in individuals over 65—this demographic shift directly expands the patient pool requiring treatment.

Advancements in healthcare have improved life expectancy, leading to a larger elderly population living long enough to develop age-related cancers. For example, in the US, the American Cancer Society reports that the median age at CRC diagnosis is 66, and the risk increases sharply after 50, peaking in the 70s and 80s. Additionally, targeted therapies and immunotherapies have expanded treatment options for elderly patients who may not tolerate aggressive chemotherapy.

Regarding end users, the colorectal cancer treatment market is segmented into hospitals, specialty clinics, home care, and others. The hospitals segment held the largest colorectal cancer treatment market share in 2024. Specialty clinics are anticipated to register the highest CAGR during 2025–2031. Hospitals serve as primary centers for the diagnosis, treatment, and post-treatment care of colorectal cancer patients, offering a comprehensive range of medical services including surgery, chemotherapy, radiation therapy, and emerging targeted therapies. Hospitals' prominence in this segment can be attributed to their advanced infrastructure, availability of specialized oncologists, multidisciplinary treatment teams, and access to state-of-the-art medical technologies. The rising incidence of colorectal cancer, especially in developing countries due to lifestyle changes, increasing aging populations, and enhanced screening programs, has significantly driven the demand for hospital-based treatment solutions. These institutions provide advanced patient care and contribute significantly to clinical research, thereby driving therapeutic advancements in colorectal cancer management.

The scope of the colorectal cancer treatment market report includes an assessment of the market performance in North America, Europe, Asia Pacific, South and Central America, and the Middle East and Africa. Regarding revenue, North America dominated the colorectal cancer treatment market in 2024. The US dominated the North America colorectal cancer treatment market in 2024. According to the American Cancer Society, in 2022, more than 1.9 million new cases of cancer were diagnosed in the nation, causing ~0.61 million deaths. The source anticipated ~2.0 million cancer diagnoses in the US in 2024. As per the data of the American Society of Clinical Oncology, colorectal cancer is the third most common cancer diagnosed in men and women in the US. The American Cancer Society (ACS) estimates that, for 2025, it will project ~154,270 new cases of colon and rectal cancer and 52,900 deaths from the disease. CRC incidence is ~33% higher in men than in women, and it is significantly elevated among certain racial and ethnic groups, including Alaska Natives, American Indians, and Black Americans. The disease typically affects older adults; the average age at diagnosis is 66, but the shifting demographics demand attention, as 10% or more of all new cases now occur in Americans under 50. While the average age of diagnosis is 66, the rise of "early-onset" CRC has led to revised screening guidelines, with major organizations recommending that average-risk individuals begin screening at age 45.

The rising incidence of cancer fuels the need for innovative treatments, such as targeted therapies and immunotherapies, in the colorectal cancer treatment market. Industry players Roche, Pfizer, Novartis, Merck, Bristol-Myers Squibb, AbbVie, Lilly, AstraZeneca, and J&J dominate the market through extensive drug pipelines and strategic mergers and acquisitions.

Bristol-Myers Squibb Co., Bayer AG, Amgen Inc., Eli Lilly and Co., Genentech Inc. (F. Hoffmann-La Roche Ltd), Pfizer Inc., Takeda Pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Regeneron Pharmaceuticals Inc., and Otsuka Holdings Co., Ltd are among the leading companies profiled in the colorectal cancer treatment market report.

In terms of geography, the market is categorized into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, South Africa, Saudi Arabia, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Contact Us

Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com